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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder
characterized by severe gastrointestinal dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral
neuropathy and leukoencephalopathy. The disease is due to a thymidine phosphorylase defect. This
enzyme catalyses the phosphorolysis of thymidine to thymine and deoxyribose 1-phosphate. For this
reason, increased levels of thymidine in plasma and urine are found in MNGIE patients. Haemodialysis
can reduce circulating plasma thymidine levels and can be beneficial in some MNGIE patients. We
developed a fast analytical method based on HPLC-ESI-MS/MS capable of identifying pyrimidine
nucleotides (thymine, cytosine, uracil) and nucleosides (thymidine, citidine, uridine) in plasma and urine
after direct dilution of the samples without pre-treatment.
In the patient studied, we observed a significant reduction of plasmatic and urinary thymidine levels
during and after dialysis. However, we noted a progressive reduction of the initial thymidine level
after some dialytic trials. This method will be useful not only for thymidine level follow-up during
dialysis in MNGIE patients but also for the improvement of the diagnosis or diagnostic suspect in other
pyrimidine defects such as dihydropyrimidine dehydrogenase deficiency, dihydropyrimidinase deficiency
and ureidopropionase deficiency. Copyright  2006 John Wiley & Sons, Ltd.
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INTRODUCTION
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is an autosomal recessive disorder defined clini-
cally by severe gastrointestinal dysmotility, cachexia, ptosis,
ophthalmoparesis, peripheral neuropathy and leukoence-
phalopathy.1 Skeletal muscle biopsies of patients have
revealed abnormalities of mtDNA and mitochondrial res-
piratory chain enzymes.2 The disease is caused by the
thymidine phosphorylase defect. This enzyme catalyses
phosphorolysis of thymidine to thymine and deoxyri-
bose 1-phosphate.3 For this reason, MNGIE patients show
increased levels of thymidine in plasma and urine. The gene
has been cloned and mapped by Nishino et al. in 1999.4
Some authors hypothesized that mitochondrial deoxyri-
bonucleotide triphosphate (dNTP) pool imbalance is likely
responsible for mutagenesis in mitochondrial DNA.5
Hemodialysis can reduce circulating plasma thymidine
levels and can be beneficial in some MNGIE patients.6
ŁCorrespondence to: G. la Marca, Department of Paediatrics,
A. Meyer Children’s Hospital, Via Luca Giordano 13, 50132
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In recent years several methods for thymidine quan-
titation have been developed using HPLC-UV or HPLC-
MS/MS.6 – 8 We have developed a fast analytical method
based on HPLC-ESI-MS/MS, capable of detecting a spec-
trum of some pyrimidine metabolites (including thymidine)
in plasma and urine. This method can be useful for the
accurate determination of the dosage of thymidine during
dialytic treatments in MNGIE patients.
EXPERIMENTAL
Materials and method
Chemical standard cytosine, cytidine, uracil, uridine,
thymine and thymidine were purchased from Sigma Aldrich
(St Louis, USA). Labelled standard Me-13C-thymidine, uracil-
1,3-15N2, thymine-2H4 and uridine-ribose-1-13C were pur-
chased from Cambridge Isotopes Laboratories (Andover,
MA, USA); cytosine-2,4-13C2,-15N3, cytidine-15N3 were pur-
chased from Aldrich (St Louis, USA).
Stock solutions (1–3 mM) were made in H2O C ammo-
nium acetate 50 mM.
All solvents were HPLC grade (Sigma Aldrich, St Louis,
USA).
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An Applied Biosystems-Sciex (Toronto, Canada) API
4000 triple-quadrupole mass spectrometer equipped with
a TurboIonSpray (TIS) source was employed in this study.
The quantitation experiments were performed using a series
PE 200 micropump (Perkin Elmer, USA) coupled to a PE
well-plate autosampler, both fully controlled by the API
4000 data system (Analyst 1.4.1 software).
The TIS source was operated in positive ion mode at
350 °C. Collision-activated dissociation (CAD) MS/MS was
performed in the LINAC Q2 collision cell, operating with
nitrogen at 10 mTorr pressure as the collision gas.
The declustering potentials (DP) for all standards (chem-
icals and labelled) were in the range of 30–80 V, the collision
energies (CE) in the range of 12–27 V and the collision exit
potential (CXP) in the range of 5–8 V (laboratory frame). MS
and MS/MS spectra were collected in continuous flow mode
by connecting the infusion pump directly to the TIS source.
A standard solution of 5 ng/µl of each chemical and labelled
standards in H2O C Ammonium Acetate 50 mM was infused
at 5 µl/min. The HPLC method had a gradient starting from
100% H2O C ammonium acetate 50 mM (solvent A) up to
100% MeOH C solvent A 50 : 50 (solvent B).
The column was a Luna C18, 5 µm, 150 mm ð 3 mm
(Phenomenex, USA) and the flow rate was 400 µl/min.
The injection loop was 40 µl and the injection volume was
3 µl.
Table 1. Declustering potentials, collision energies, collision
exit potentials and transitions of each compound in positive
ESI mode
Compound
DP
(V)
CE
(V)
CXP
(V)
Q1
(Th)
Q3
(Th)
Cytosine 51 27 8 112.1 95.0
Cytosine-2,4-13C2,-15N3 51 27 8 117.1 100.0
Cytidine 35 23 8 244.2 112.1
Cytidine-15N3 35 23 8 247.2 115.1
Uracil 80 24 5 113.1 70.0
Uracil-1,3-15N2 80 24 5 115.1 71.0
Uridine 30 15 6 245.2 113.1
Uridine-ribose-1-13C 30 15 6 246.2 113.1
Thymidine 30 12 8 243.2 127.1
Me-13C-thymidine 30 12 8 244.2 128.1
Thymine 80 24 6 131.1 114.1
Thymine-2H4 80 24 6 127.1 110.1
The acquired data were processed using the Analyst 1.4.1
proprietary software including the ‘Explore’ option for chro-
matographic and spectral interpretation. For quantitative
data, MS/MS spectra were collected operating in multiple
reaction monitoring (MRM) mode for all compounds. MRM
[Thymidine+H]+
[13C-Thymidine+H]+
[M-116+H]+
[M-116+H]+
Figure 1. Product ion scan of thymidine and 13C-thymidine.
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transitions, DP, CE and CXP for all pyrimidines are reported
in Table 1.
The product ion scan spectra of thymidine and
13C-thymidine are reported in Fig. 1.
Samples
Dietary and drug interferences are the major threat to the
diagnosis of purine/pyrimidine defects, as many foods,
beverages and drugs can contain, especially, purines. We
collected the urine and plasma of healthy controls who were
recommended to avoid, 48 h before the collection, coffee,
tea, chocolate, soft drinks, bananas, not-home-made sweets,
liquorice, red meat and, when possible, antibiotics, aromat-
ics (paracetamol, aspirin) and purine/pyrimidine analogues
such as fluorouracil and allopurinol. The best condition was
Table 2. Intra-day reproducibility of pyrimidines at various concentrations
Unspiked urine (creatinine 3.59 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 1 7.5 12.2 0 1 19
Average 0.95 7.56 12.43 0.00 0.97 18.7
SD 0.12 0.44 0.96 – 0.1 1.07
CV% 12.43 5.82 7.72 – 10.31 5.72
Accuracy 95.00 100.80 101.89 – 97.00 98.42
Spiked urine (creatinine 3.59 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 21.36 27.86 22.56 20.36 31.36 39.36
Average 20.86 28.44 24.01 19.74 32.01 37.56
SD 0.61 1.3 4.3 3.9 0.99 4.02
CV% 2.92 4.57 17.91 19.76 3.09 10.70
Accuracy 97.68 102.08 106.43 96.95 102.07 95.43
Spiked urine (creatinine 2.11 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 10.03 15.44 18.08 10.11 10.96 24.47
Average 9.45 13.95 19.04 8.87 11.13 25.29
SD 0.41 4.6 2.6 1.6 0.32 2.1
CV% 4.33 32.97 13.66 18.04 2.88 8.30
Accuracy 94.2 90.35 105.31 87.73 101.55 103.35
Spiked urine (creatinine 2.11 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 20.03 35.44 28.08 20.11 20.96 34.47
Average 20.23 33.12 27.44 19.88 22.04 35.82
SD 1.08 4.6 1.9 3.1 2.32 3.1
CV% 5.31 13.89 6.92 15.59 10.53 8.65
Accuracy 100.98 93.45 97.72 98.86 105.15 103.92
Spiked urine (creatinine 0.44 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 11 16.94 15.28 10.01 10.13 21.11
Average 11.29 17.12 16.02 9.91 11.01 20.63
SD 0.73 2.7 1.5 1.1 0.57 1.71
CV% 6.46 15.77 9.36 11.10 5.18 8.29
Accuracy 102.61 101.06 104.84 99.00 108.69 97.73
Spiked urine (creatinine 0.44 mM)
Thymidine Thymine Cytidine Cytosine Uridine Uracil
Expected value 26 31.94 30.28 25.01 25.13 46.11
Average 25.98 30.12 30.02 25.06 24.44 44.86
SD 1.74 4 1.4 3.1 2.57 5.08
CV% 6.69 13.28 4.66 12.37 10.52 11.32
Accuracy 99.92 94.30 99.14 100.20 97.25 97.29
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to perform analysis on urine collected for 24 h or, when
not possible, on urine randomly collected and normalized
to creatinine. Our reference value for thymidine in urine
was 0.09–1.34 µmol/mmol creatinine (5–95th percentiles,
based on controls D 80). Plasma thymidine was normally not
detectable or was present only in traces.
Sample preparations
Urine and plasma samples were diluted 1 : 20 with H2O C
ammonium acetate 50 mM, added with labelled standards
(conc. 100 µM) and directly injected in the LC/MS/MS system
for analysis. Urine and plasma samples were collected and
analysed on the same day. If a rapid analysis was not
possible, samples were frozen to 20° C immediately to
avoid degradation. No addition of preservatives such as
chloroform or toluene was made, to avoid electrospray
suppression. For this study different urine samples with
different creatinine concentrations were spiked with a
mixture of chemical standards. Sample dilution rate (20
times) and injection volume (3 µl) were selected in order
not to overload the chromatographic column even after a
consistent number of sample injections (0.3 µl of original
urine was introduced through each single injection). The
injection volume was selected after several trials with
different injection volumes. The dilution step made with
H2O C ammonium acetate 50 mM and no organic solvent
was intended to pack the injected sample plug at the front
end of the column.
In order to assess the robustness of the method, sev-
eral urine and plasma samples (with very different densities
and creatinine concentrations) were processed several times.
Samples were processed and read in comparison with aque-
ous standard (results are stated without normalization for the
creatinine content). As an example, Table 2 reports the thymi-
dine data obtained for three samples with low (0.44 mmol/l),
medium (2.11 mmol/l) and high (3.59 mmol/l) creatinine
concentrations. The resulting intra-day reproducibility was
below 6.7% for values above 10 µmol/l. In an inter-day repro-
ducibility test, the values were better than 3.6% (Table 3).
With the proposed parameters, the estimated thymidine
limit of detection (3 ð SD) was less than 0.01 µM (similar val-
ues for all other pyrimidines). We found the worst limit of
detection in the case of uracil of about 0.08 µmol/l.
No deterioration in column efficiency was observed after
analyses of 125 urine and 80 plasma samples.
Case report
The proband was a woman born in 1976 who died at the
age of 28. Her parents were consanguineous. No other
family members, including an older and a younger brother,
had any neurological or gastrointestinal abnormalities.
The onset of symptoms was in the first months of life
with vomiting and diarrohea; when 10 years old, she
presented diarrohea, borborygmia and abdominal pain.
Gastrointestinal investigations and intestinal biopsy showed
no lesion.
At the age of 19 she presented impaired growth: another
biopsy showed nonspecific chronic inflammation.
At the age of 20 the patient was examined for unsteady
gait: Electromyography (EMG) showed neurogenic changes
in muscle, and an axonal, mostly sensory, peripheral
neuropathy.
She developed bowel obstruction and went for operative
intervention with surgical resection several times.
At the age of 22, the patient was referred to our
department for abdominal pain, diarrhoea, diverticula and
dilatation of the bowel. ECG, echocardiography, audiometry
and neuropsychological examinations were normal, as well
as plasma creatine kinase and plasma lactate. The retina was
normal. Examination revealed mild ptosis, ophthalmoplegia,
areflexia, sensory ataxia and diffuse muscle weakness
associated with pronounced cachexia. She was 152 cm tall
(<3rd percentile) and weighed 30 kg (<3rd percentile).
Gastrointestinal investigations showed chronic pseudo-
obstruction due to dysmotility and dilation. Brain MRI
demonstrated leukoencephalopathy.
MNGIE was suspected for specific clinical symptoms
(intestinal pseudo-obstructions, leukoencephalopathy and
peripheral neuropathy) and was diagnosed by markedly
raised plasma thymidine and severely reduced thymidine
phosphorylase activity in leukocytes.6 Sequence analysis of
the patient’s TP gene revealed homozygosity for the muta-
tion g3867a.6 Analysis of muscle mitochondrial enzyme was
normal, and muscle histochemical analysis did not show any
abnormalities. A tentative therapeutic trial with benzbro-
marone was started without any clinical improvement.
She underwent three weekly dialysis treatments to
reduce thymidine levels. We analysed via our tandem mass
spectrometric method, plasma and urine samples collected
before and after dialysis. We demonstrated a gradual
reduction of thymidine levels during dialytic treatment.
RESULTS AND DISCUSSION
We have developed a new and fast analytical method
that allows the quantification of pyrimidine metabolites in
biological fluids such as urine and plasma.
Table 3. Inter-day (6 days) reproducibility on spiked urine
Spiked urine (creatinine 0.44 mM)
Thymidine Thymine Citidine Cytosine Uridine Uracil
Expected value 11 16.94 15.28 10.01 10.13 21.11
Average 11.07 17.33 15.55 10.81 11.91 21.35
SD 0.39 0.7 0.95 1 0.34 1.01
CV% 3.52 4.04 6.11 9.25 2.85 4.73
Accuracy 100.65 102.30 101.77 107.99 117.57 101.14
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Figure 2. LC-MS/MS pyrimidine standards profile.
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Figure 3. Urine thymidine level: MNGIE patient versus control.
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Figure 4. Plasma thymidine level in the MNGIE patient.
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Figure 5. Comparison between pre- and post-dialysis urine thymidine level in the MNGIE patient.
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Figure 6. Thymidine level reduction after haemodialysis used
as therapeutic approach.
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Figure 7. Long-term thymidine profile: the graph shows that
repetitive dialysis can reduce the maximum basal level of
circulating thymidine in a MNGIE patient.
The proposed method is characterized by a fast and very
simple sample preparation. Calibration is made internally
with aqueous labelled standards. Instrumental analysis time
is less than 17 min. Chromatography combined with the
specificity provided by tandem mass spectrometry detection
allows a fast and specific procedure for the determination
of some pyrimidines. At the moment we are able to
identify pyrimidine nucleotides (thymine, cytosine, uracil)
and nucleosides (thymidine, citidine, uridine) (Fig. 2). This
method allowed the quantification of urine (Fig. 3) and
plasma (Fig. 4) thymidine levels in a MNGIE patient before,
during and after dialysis used as therapeutic approach
(Figs 5, 6).
In the patient studied, we observed a significant reduction
of plasmatic and urinary thymidine levels during and after
dialysis. However, we noted a progressive reduction of the
initial thymidine level after some dialytic trials (Fig. 7).
This method will be useful not only for thymidine
level follow-up during dialysis in MNGIE patients but also
for improvement of the diagnosis or diagnostic suspect
in other pyrimidine defects such as dihydropyrimidine
dehydrogenase deficiency, dihydropyrimidinase deficiency
and ureidopropionase deficiency.
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